{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:31:06Z","timestamp":1776400266247,"version":"3.51.2"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The outcome of venous thromboembolism in patients with cancer is worse than in patients without cancer, with a higher risk of recurrences, bleeding and death. However, these risks appear to vary depending on the cancer type. While in some tumours the risk of recurrences outweighs the risk of bleeding, in others the risk of major bleeding (MB) during the anticoagulation markedly exceeds the risk of a recurrent event. Balancing these risks could be helpful to tailor the management of cancer-associated thrombosis (CAT) and improve outcomes. In this article, published data from recent randomized clinical trials as well as from some large registries that have reported separated outcomes of CAT depending on cancer type were reviewed. A careful balance of the risk of recurrences and MB events could provide useful insights for clinicians for individualizing treatment strategies in order to improve the outcomes of CAT, as well as for the design of future clinical trials.<\/jats:p>","DOI":"10.1055\/a-2535-7400","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T19:03:02Z","timestamp":1739214182000},"page":"1053-1059","source":"Crossref","is-referenced-by-count":2,"title":["Differences in the Outcome of Cancer-Associated Thrombosis Depending on Cancer Type"],"prefix":"10.1055","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8850-8866","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Lecumberri","sequence":"additional","affiliation":[{"name":"Hematology Service, Cancer Center Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Marcos-Jubilar","sequence":"additional","affiliation":[{"name":"Hematology Service, Cancer Center Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Hermida","sequence":"additional","affiliation":[{"name":"Hematology Service, Cancer Center Universidad de Navarra, Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-9883","authenticated-orcid":false,"given":"Pedro","family":"Ruiz-Artacho","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Cl\u00ednica Universidad de Navarra, Madrid, Spain"},{"name":"Consorcio de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"J F Timp","year":"2013","journal-title":"Blood"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0044-1779672","article-title":"Risk of venous thromboembolism by cancer type: a network meta-analysis","volume":"50","author":"M B Betts","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"14","key":"ref4","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"S 01","key":"ref5","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0049-3848(16)30106-2","article-title":"Predictors of recurrent venous thromboembolism and bleeding on anticoagulation","volume":"140","author":"L A Menapace","year":"2016","journal-title":"Thromb Res"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MBC.0b013e328341f030","article-title":"Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies","volume":"22","author":"M L Louzada","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2020.07.021","article-title":"Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia","volume":"195","author":"R Lecumberri","year":"2020","journal-title":"Thromb Res"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","article-title":"Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study","volume":"185","author":"F I Mulder","year":"2020","journal-title":"Thromb Res"},{"issue":"20","key":"ref12","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"G Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/cancers14030559","article-title":"A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: priority","volume":"14","author":"J H Kim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"M C Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"25","key":"ref16","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"C E Chee","year":"2014","journal-title":"Blood"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"I Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1055\/s-0038-1656542","article-title":"Clinical characteristics and outcomes of patients with lung cancer and venous thromboembolism","volume":"2","author":"P Ruiz-Artacho","year":"2018","journal-title":"TH Open"},{"issue":"17","key":"ref19","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.3390\/cancers14174127","article-title":"Cancer histology and natural history of patients with lung cancer and venous thromboembolism","volume":"14","author":"P Ruiz-Artacho","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.lungcan.2021.05.019","article-title":"Thromboembolism in ALK+ and ROS1+ NSCLC patients: a systematic review and meta-analysis","volume":"157","author":"V W Zhu","year":"2021","journal-title":"Lung Cancer"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1055\/s-0038-1642009","article-title":"Clinical course of venous thromboembolism in patients with pancreatic cancer: insights from the RIETE registry","volume":"118","author":"C Frere","year":"2018","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"102172","DOI":"10.1016\/j.rpth.2023.102172","article-title":"Acute venous thromboembolism in patients with brain cancer: clinical course","volume":"7","author":"C Becattini","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"J I Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"16","key":"ref24","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","article-title":"ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis","volume":"6","author":"M Giustozzi","year":"2022","journal-title":"Blood Adv"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1055\/a-1777-4006","article-title":"Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors","volume":"122","author":"R Lecumberri","year":"2022","journal-title":"Thromb Haemost"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejim.2021.05.029","article-title":"Risk factors of recurrence in patients with cancer-associated venous thromboembolism","volume":"91","author":"Y Nishimoto","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism- from the COMMAND VTE registry","volume":"84","author":"Y Nishimoto","year":"2020","journal-title":"Circ J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejim.2024.04.012","article-title":"Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism","volume":"127","author":"Y Nishimoto","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/a-2145-7238","article-title":"A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer","volume":"124","author":"A T Cohen","year":"2024","journal-title":"Thromb Haemost"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"131271","DOI":"10.1016\/j.ijcard.2023.131271","article-title":"Risk of recurrent cancer-associated venous thromboembolism: a Danish nationwide cohort study","volume":"390","author":"A G Ording","year":"2023","journal-title":"Int J Cardiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2022.11.005","article-title":"Influence of primary cancer site on clinical outcomes of anticoagulation for associated venous thromboembolism","volume":"221","author":"W E Wysokinski","year":"2023","journal-title":"Thromb Res"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"R D McBane Ii","year":"2023","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"M A de Winter","year":"2022","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"M L Louzada","year":"2012","journal-title":"Circulation"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1160\/TH17-02-0116","article-title":"Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry","volume":"117","author":"A Alatri","year":"2017","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3324\/haematol.2019.222828","article-title":"Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"105","author":"A Delluc","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"A A Khorana","year":"2008","journal-title":"Blood"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1160\/TH16-11-0840","article-title":"Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis","volume":"117","author":"A J Tafur","year":"2017","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/a-2418-3960","article-title":"Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model","volume":"125","author":"V R Lanting","year":"2025","journal-title":"Thromb Haemost"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2023.06.015","article-title":"Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning","volume":"228","author":"A J Mu\u00f1oz","year":"2023","journal-title":"Thromb Res"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s12094-024-03586-2","article-title":"Prediction model for major bleeding in anticoagulated patients with cancer-associated venous thromboembolism using machine learning and natural language processing","volume":"27","author":"A J Mu\u00f1oz Mart\u00edn","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"04","key":"ref42","first-page":"834","article-title":"Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism","volume":"110","author":"R Lecumberri","year":"2013","journal-title":"Thromb Haemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2535-7400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:45:23Z","timestamp":1761867923000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2535-7400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2535-7400","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,10]]},"published":{"date-parts":[[2025,2,10]]}}}